Andrea Apolo, Arjun Balar, Robert Dreicer, Ashish Kamat

Andrea Apolo, MD

Investigator and Lasker Scholar
Chief, Bladder Cancer Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Dr. Apolo is a Board Certified Medical Oncologist, Lasker Clinical Research Scholar, Tenure-Track Investigator, and Chief of the Bladder Cancer Section of the Genitourinary Malignancies Branch of the National Cancer Institute in Bethesda, Maryland. She is a graduate of Albert Einstein College of Medicine in Bronx, New York and completed clinical training in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City, New York. Following her residency, Dr. Apolo completed a Medical Oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City, New York.

Dr. Apolo is dedicated to improving the lives of patients with genitourinary tumors. Her research involves designing and implementing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is developing targeted therapies for bladder cancer and rare genitourinary tumors, including angiogenesis inhibitors, agents that target MET, and immunotherapies and in identifying molecular alterations that will serve as targets for individualized treatment strategies.

Back to top

Arjun Balar, MD

Director, Genitourinary Medical Oncology Program
NYU Langone Perlmutter Cancer Center
New York, New York

Dr. Balar is an Associate Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center in New York, New York. Dr. Balar received his Medical Degree from the University of South Florida–Morsani College of Medicine in Tampa, Florida, as a member of the Alpha-Omega-Alpha Honor Medical Society. He completed his Internal Medicine residency at New York-Presbyterian–Weill Cornell Medical Center in New York, New York, and went on to complete a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York, New York, where he focused his research efforts entirely on novel therapies in muscle-invasive and metastatic bladder cancer.

Dr. Balar has focused primarily on cisplatin-ineligible patients with the goal of identifying better tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer, with a particular focus on novel immunotherapies and combinations.

Back to top

Robert Dreicer, MD, MS, MACP, FASCO

Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Section Head, Medical Oncology
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Cancer Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine in Charlottesville, Virginia. Dr. Dreicer previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center in Cleveland, Ohio. He is Board Certified in Internal Medicine and Medical Oncology. His areas of specialization are the management of genitourinary malignancies, and the design and conduct of clinical trials in urologic oncology.

Dr. Dreicer received his BS Degree at Colorado State University and his MS Degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his Medical Degree from the University of Texas Medical School in Houston, Texas. He completed an Internal Medicine residency at Indiana University in Indianapolis, Indiana, followed by a Medical Oncology Fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology and served as Principal Investigator in a large number of studies in genitourinary neoplasms. He previously served as Co-Chair of the National Cancer Institute Genitourinary Cancers Steering Committee and is a member of the editorial board of New England Journal of Medicine’s Journal Watch Hematology and Oncology. In October 2016, he was awarded Mastership in the American College of Physicians.

Back to top

Ashish Kamat, MD, MBBS, FACS

Professor of Urologic Oncology
Wayne B. Duddlesten Professor of Cancer Research
President, International Bladder Cancer Group (IBCG)
University of Texas, MD Anderson Cancer Center
Houston, Texas

Dr. Kamat is a Professor of Urologic Oncology and Wayne B. Duddlesten Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. He is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ sparing and minimally invasive techniques. Dr. Kamat maintains an active research portfolio in this area with a focus on developing novel therapies, and identifying predictors of response to therapy (eg, intravesical immunotherapy), as a first step toward personalized cancer therapeutics. He has initiated, led, and been active in several large studies, including multinational trials in bladder cancer with findings published in high-impact journals.

Dr. Kamat is listed in ‘Who’s Who in Medicine’ and ‘Best Doctors in America’ and has won the ‘Compassionate Doctor Award’ from patient groups. He is President of the International Bladder Cancer Group and President of the International Bladder Cancer Network. He is also Associate Editor, European Urology Oncology and Associate Cancer Center Director, RFHNH, Mumbai, India.

Back to top